June 1, 2020

Brent Ragans named President of Ferring US

  • Ragans is now responsible for Ferring US commercial, manufacturing and development operations
  • Ragans joined Ferring, a world leader in reproductive medicine, in 2012 and was named US Chief Commercial Officer in 2016

Parsippany, NJ – June 1, 2020 – Ferring Pharmaceuticals (US) announced today that Brent Ragans has been appointed as President. In this role Mr. Ragans oversees the commercial, manufacturing and development operations of the global Ferring Pharmaceuticals Group in the United States.

Ferring is entering a new phase in which it will expand its leadership in Reproductive Medicine and Maternal Health, Orthopaedics and Gastroenterology,” said Mr. Ragans. “Among the highlights, we look forward to seeking regulatory approval for what may become the world’s first approved microbiome-based therapy.”  

Originally from Jacksonville, Florida, Brent Ragans has more than 30 years’ experience in the pharmaceutical business. He joined Ferring Pharmaceuticals (US) as vice president of commercial operations in 2012 and was named chief commercial officer in 2016. Prior to Ferring, he led North American consumer healthcare strategy and corporate development for Sanofi. Earlier during 12 years at Sanofi, he managed major business units, including general therapeutics, specialty markets, and cardiovascular, and led teams of more than 2500 representatives.

As the President of Ferring US, Mr. Ragans reports to Aaron Graff, Global Chief Commercial Officer, Member of the Executive Committee and Executive Chairman of Ferring Holding Inc. (US). Mr. Ragans succeeds Paul Navarre, who is leaving the company.

“Brent has been one of the key architects of our US business since joining Ferring eight years ago,” said Aaron Graff, Global Chief Commercial Officer, Member of the Executive Committee and Executive Chairman of Ferring Holding Inc. (US). “His track record of success, broad background and deep knowledge of Ferring positions him well to lead the company into its next successful chapter.”


About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. In the United States, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and orthopaedics. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com



# # #

For more information, please contact

Patrick Gorman                                                             
Director, External Communications
(862) 286-5035 (direct)

(973) 722-6335 (mobile)

This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

All information on this site is intended for US audiences only.

CERVIDIL, CLENPIQ, ENDOMETRIN, EUFLEXXA, FIRMAGON, MENOPUR, NOCDURNA, NOVAREL, and ZOMACTON are registered trademarks of Ferring B.V. INVOCELL is a registered trademark of INVO BioScience. ORTIKOS is a trademark of Sun Pharma Global FZE.

©2008-2020 Ferring Pharmaceuticals.  US-CORP-2000031